Presently, over 240 ADC therapy candidates are being evaluated

With six marketed drugs, ADCs are presently recognized as a potent class of targeted anticancer therapies, with the potential to be used to treat a variety of other disease indications. The success of such products can be attributed to their ability to effectively identify and eliminate disease associated cells / pathogens, with substantially lower risk of treatment related side effects.
 
To order this 600+ page report, which features 190+ figures and 280+ tables, please visit this link
 
The USD 15 billion (by 2030) financial opportunity within this market has been analyzed across the following segments:
Type of Payload
MMAE
DM4
Camptothecin
DM1
MMAF
Others
  • Type of Linker
  • VC
  • Sulfo-SPDB
  • SMCC
  • VA
  • Hydrazone
  • Others
Target Indication
  • Breast cancer
  • Lymphoma
  • Leukemia
  • Urothelial cancer
  • Lung cancer
  • Ovarian cancer
  • Others
 
Target Antigen
  • CD30
  • HER2
  • CD22
  • CD33
  • Others
Technology Providers
  • Seattle Genetics
  • ImmunoGen
  • StemCentRx
  • Immunomedics
  • Others

Key Geographical Regions
North America
Europe
Asia Pacific
 
The Antibody Drug Conjugates Market (5th Edition), 2019-2030 report features the following companies, which we identified to be key players in this domain: 
Bristol Myers Squibb
GlaxoSmithKline
Incyte
Novartis
Trillium Therapeutics
 
Table of Contents
 
1. Preface

2. Executive Summary

3. Introduction


Market Overview


5. Company and Drug Profiles


6. Key Therapeutic Areas


7. Key Opinion Leaders


8. Target Competitiveness Analysis


9. Partnerships and Collaborations


10. Funding and Investment Analysis


11. Patent Analysis


12. Academic Grants


13. Key Commercialization Strategies
14. Promotional Analysis
 
15. Combination Therapies
 
16. Novel Conjugation Technology Platforms
 
17. Assessment of Non-Clinical Data, First in Human Dosing
 
18. Cost Price Analysis
 
19. Case Study: Contract Manufacturing of ADC
 
20. Case Study: Companion Diagnostics for ADC Therapeutic
 
21. Market Forecast and Opportunity Analysis
 
22. Swot Analysis


23. Conclusion
24. Executive Insights
25. Appendix 1: Tabulated Data
 
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/antibody-drug-conjugates-market-5th-edition-2019-2030/270.html
 
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
[email protected]  

You may also like

Discussion

No comments yet... Be the first to leave a reply! Login here

avatar
BenJ
0 Karma
415 Posts

Made with by Mamby